Fucimax™

Sodium Fusidate 250 mg

1703

Presentation
Fucimax™ Tablet: Each tablet contains Sodium Fusidate BP 250 mg.

Description
Sodium Fusidate is a potent anti-staphylococcal agent with unusual ability to penetrate tissue. Bactericidal levels have been assayed in bone and necrotic tissue. Concentrations of 0.03 - 0.12 micrograms/ml inhibit nearly all strains of *Staphylococcus aureus*. Fusidic acid is active against *Staphylococcus epidermidis* and methicillin-resistant staphylococci.

Indications and Uses
Sodium Fusidate is indicated in the treatment of all staphylococcal infections due to susceptible organisms such as:

- cutaneous infections
- osteomyelitis
- pneumonia
- septicaemia
- wound infections
- endocarditis
- superinfected cystic fibrosis

Dosage and administration

For staphylococcal skin infections:
Tablet
Adults and children from 12 years: 250 mg 2 times a day for 5-10 days.

For penicillin-resistant staphylococcal infections such as osteomyelitis, pneumonia, septicemia, wound infections, endocarditis, superinfected cystic fibrosis:
Tablet
Adults and children from 12 years: 500 mg 3 times a day. Dose can be increased to 1 gram 3 times a day for severe infections.

*Oral suspension**
Children 1-11 months: 15 mg/kg 3 times a day
Children 1-4 years: 250 mg 3 times a day
Children 5-11 years: 500 mg 3 times a day
Children 12-17 years: 750 mg 3 times a day
Adults: 750 mg 3 times a day
*Oral suspension is not available for Fucimax.

Elderly:
No dosage adjustment is necessary in the elderly.

Since Sodium Fusidate is excreted in the bile, no dosage modifications are needed in renal impairment.

No dosage adjustment is required in patients undergoing haemodialysis as it is not significantly dialysed.

Side-effects
The most frequently reported undesirable effects to Sodium Fusidate are dose dependent gastrointestinal disorders like diarrhoea, vomiting, abdominal pain, dyspepsia, nausea. Various skin reactions, reversible jaundice, haematological disorders and generalised hypersensitivity reactions have been reported. Leukopenia, thrombocytopenia, anemia, anorexia, drowsiness, dizziness, headache, cholestasis, urticaria, pruritus, rash, rhabdomyolysis may rarely occur.

Precautions
Periodic liver function tests should be carried out when the product is given for prolonged periods and to patients with liver dysfunction.

Use in pregnancy & lactation
Pregnancy: Based on animal data does not cause fetal harm. Do not use unless the potential benefit justifies the potential risk.
Lactation: Caution should be exercised when administered to a nursing woman.

Contraindications
Hypersensitivity to any of the ingredients of this formulation. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Drug interactions
Statin treatment should be discontinued throughout the duration of the Sodium Fusidate treatment. Co-administration of Sodium Fusidate systemically and Ciclosporin has been reported to cause increased plasma concentration of Ciclosporin.

Overdose
Acute symptoms of overdose include gastrointestinal disturbances and possible effects on liver function. Treatment should be restricted to symptomatic and supportive measures.

Storage
Do not store above 30^0 C. Keep out of the reach of children.

Commercial Pack
Fucimax™ Tablet: Each box contains 1 blister strip of 10 tablets.

Manufactured by
Incepta Pharmaceuticals Ltd
Savar, Dhaka, Bangladesh
™ Trademark

FUT

V.N.01